ANDA Approval Records Likely To End
Record Approvals Expected To End As US FDA Mops Up Backlog
CDER director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.
